Trial · NCT03198728
Results by group313
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 313
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Male Hypogonadal Subjects With Average NaF/EDTA Plasma Total Testosterone (T Cavg) Within the Normal Range Using Oral SOV2012-F1. | SOV2012-F1 Treated | 166 | Participants | ||
| Percentages of Participants in Each Category for Maximum Plasma Concentration | SOV2012-F1 Treated | T Cmax < 1200 ng/dL for SOV2012-F1; T Cmax < 1500 ng/dL for Andro-gel after 90 days | 76.9 | percentage of actual number of subjects | |
| Percentages of Participants in Each Category for Maximum Plasma Concentration | Andro-gel™ Treated | T Cmax < 1200 ng/dL for SOV2012-F1; T Cmax < 1500 ng/dL for Andro-gel after 90 days | 92.2 | percentage of actual number of subjects | |
| Percentages of Participants in Each Category for Maximum Plasma Concentration | SOV2012-F1 Treated | T Cmax 1440 to 2000 ng/dL for SOV2012-F1; T Cmax 1800 to 2500 ng/dL for Andro-gel after 90 days | 7.5 | percentage of actual number of subjects | |
| Percentages of Participants in Each Category for Maximum Plasma Concentration | Andro-gel™ Treated | T Cmax 1440 to 2000 ng/dL for SOV2012-F1; T Cmax 1800 to 2500 ng/dL for Andro-gel after 90 days | 2.2 | percentage of actual number of subjects | |
| Percentages of Participants in Each Category for Maximum Plasma Concentration | SOV2012-F1 Treated | T Cmax > 2000 ng/dL for SOV2012-F1; T Cmax > 2500 ng/dL for Andro-gel after 90days | 3.2 | percentage of actual number of subjects | |
| Percentages of Participants in Each Category for Maximum Plasma Concentration | Andro-gel™ Treated | T Cmax > 2000 ng/dL for SOV2012-F1; T Cmax > 2500 ng/dL for Andro-gel after 90days | 1.1 | percentage of actual number of subjects | |
| Change From Baseline in the IPSS | SOV2012-F1 Treated | Baseline | 4.4 | Standard Deviation 4.12 | score on a scale |
| Change From Baseline in the IPSS | Andro-gel™ Treated | Baseline | 5.4 | Standard Deviation 4.94 | score on a scale |
| Change From Baseline in the IPSS | SOV2012-F1 Treated | Change from baseline (Visit 8 - Day 90) | 0.2 | Standard Deviation 3.56 | score on a scale |
| Change From Baseline in the IPSS | Andro-gel™ Treated | Change from baseline (Visit 8 - Day 90) | 0.7 | Standard Deviation 3.72 | score on a scale |
| Change From Baseline in the IPSS | SOV2012-F1 Treated | Change from baseline (Visit Day 365) | 0.6 | Standard Deviation 3.99 | score on a scale |
| Change From Baseline in the IPSS | Andro-gel™ Treated | Change from baseline (Visit Day 365) | 1.0 | Standard Deviation 3.73 | score on a scale |
| Change From Baseline in the Psychosexual Daily Questionnaire (PDQ) | SOV2012-F1 Treated | Overall Level of sexual desire Visit 3 - Day 1 (baseline) | 1.990 | Standard Deviation 1.4195 | score on a scale |
| Change From Baseline in the Psychosexual Daily Questionnaire (PDQ) | Andro-gel™ Treated | Overall Level of sexual desire Visit 3 - Day 1 (baseline) | 2.039 | Standard Deviation 1.5659 | score on a scale |
| Change From Baseline in the Psychosexual Daily Questionnaire (PDQ) | SOV2012-F1 Treated | Overall Level of sexual desire Visit 8 - Day 90 | 1.674 | Standard Deviation 1.6851 | score on a scale |
| Change From Baseline in the Psychosexual Daily Questionnaire (PDQ) | Andro-gel™ Treated | Overall Level of sexual desire Visit 8 - Day 90 | 1.256 | Standard Deviation 1.5583 | score on a scale |
| Change From Baseline in the Psychosexual Daily Questionnaire (PDQ) | SOV2012-F1 Treated | Overall Level of sexual desire Visit Day 365 | 1.552 | Standard Deviation 1.7596 | score on a scale |
| Change From Baseline in the Psychosexual Daily Questionnaire (PDQ) | Andro-gel™ Treated | Overall Level of sexual desire Visit Day 365 | 1.372 | Standard Deviation 1.6968 | score on a scale |
| Change From Baseline in the Psychosexual Daily Questionnaire (PDQ) | SOV2012-F1 Treated | Without a Partner Visit 3 - Day 1 (baseline) | 0.754 | Standard Deviation 0.9640 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03198728/results